|
|
Jonah Lomu withdraws from charity boxing event - New Zealand Herald |
New Zealand Herald
The 36-year-old is on dialysis and the future of his transplanted kidney appears bleak. At last night's IRB rugby awards ceremony in Auckland, Lomu said that he had withdrawn from the event. Doctors at Auckland City Hospital have told the former All
|
|
|
DaVita Inc. Schedules 3rd Quarter 2011 Investor Conference Call - Bradenton Herald |
Bradenton Herald
DaVita Inc., a Fortune 500® company, is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients' quality of life by
|
|
Dialysis treatments - Chicago Tribune |
Chicago Tribune
Your dialysis article ("Study finds risk with 2-day gap in dialysis treatment" Oct. 19) stressed the potential added risks of "long break" (a two day gap) treatments versus the normal every-other-day treatment. Apparently the jury is still out on this.
|
|
Lantheus Medical Imaging Awarded Three-Year Supplier Agreements with the ... - EON: Enhanced Online News (press release) |
EON: Enhanced Online News (press release)
History of a prior allergic reaction to a gadolinium-based contrast agent. acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period. In these patients, avoid use of gadolinium-based ...
Lantheus Medical Imaging Awarded Three-Year Supplier Agreements with the
|
|
Public Citizen slams rivaroxaban and ROCKET-AF - Cardiovascular Business |
Cardiovascular Business
Despite receiving praise from the FDA's Cardiovascular and Renal Drug Advisory Committee, the anticoagulant rivaroxaban (Xarelto, Bayer/Johnson & Johnson) is now getting scrutiny from Public Citizen. In a letter dated Oct. 20 and sent to the FDA,
|
|
|
|
|
<< Start < Prev 631 632 633 634 635 636 637 638 639 640 Next > End >>
|
|
Page 631 of 2630 |